PharmaCyte Biotech, Inc. has switched its accounting firm to Grassi & Co. starting October 14.

Oct 16, 2026, 5:48 PM ETPaperworkRead the original at SEC EDGAR

Neutral

PharmaCyte changed accounting firms, but the filing reports no dispute or adverse audit opinion. It also repeats weaknesses in financial checks and review, so the filing does not change the company's outlook.

PMCB · PharmaCyte Biotech, Inc.

AI read · Neutral

The AI's read

The filing gives no sign the change followed a fight over the books. The outgoing firm's reports had no adverse opinion, but PharmaCyte still reports weaknesses in financial checks and management review. Together, these facts do not point to a clear change in the company's outlook.

Get alerts for PMCB

Follow PharmaCyte Biotech, Inc. (PMCB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PMCB

Free on the App Store and Google Play, or on the web.